 This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b alb-IFNin combination with ribavirin compared with peginterferon alfa-2a PEGASYS or PEG-IFNa2a in combination with ribavirin in subjects with chronic hepatitis C, genotype 1 who are IFNa treatment naive. 